Loading
A phase 3 trial of Sacituzumab govitecan, Topotecan, Amrubicin in small-cell lung cancer, run by Gilead Sciences, now recruiting.
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06801834 by Gilead Sciences, with 695 participants planned, started 2025-04-04 and due to reach its primary completion in 2029-10. Interventions recorded: Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available). Conditions listed: Extensive Stage Small Cell Lung Cancer (ES-SCLC). No results are recorded here; the registry entry is the source.
Shares Amrubicin, Lurbinectedin, Topotecan, Extensive-stage small-cell lung cancer.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Lurbinectedin, Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).